RESUME

Name: Saeed A. Qureshi

Contact Information: 56 Gleeson Way, Ottawa, ON, K2J 4Y7, CANADA
(Tel: 613-825-1927; Cell: 613 797 9815)
Email: Principal@PharmacoMechanics.com

JOB HISTORY AND WORK EXPERIENCES:

2015 - Present

Principal at PharmacoMechanics: Providing training and consulting services in the area of establishing quality standards for pharmaceutical products, in particular oral products (such as tablets/capsules), by predicting plasma drug levels from in vitro drug release/dissolution results – utilizing scientific expertise of; pharmacokinetics, biopharmaceutics, drug dissolution testing, and analytical chemistry and thorough knowledge and understanding of various related concepts (such as SUPAC, BCS, IVIVC, QbD) and standards and guidelines (e.g., FDA, USP, ICH). (www.pharmacomechanics.com). Providing consultation concerning methods/tests development, valiadation, and their application for medicines, including biological agents such as RNA/DNA, viruses, and vaccines.

2010 - Present

Owner & Moderator of blogs (www.bioanalyticx.com, *www.drug-dissolution-testing.com*): Providing authoritative scientific commentaries and articles on biopharmaceutics and assessment of the quality of medicinal and therapeutic agent products.

1985 to 2015

Senior Research Scientist, Bureau of Biopharmaceutical Sciences, Therapeutic Products Directorate, HPFB, Health Canada, Ottawa, Canada, K1A 0L2.

Assignments: Laboratory-based research in the biopharmaceutical discipline as applies to assessing and establishing pharmaceutical products' safety, efficacy, and quality.

Expertise: (1) Quality assessment of pharmaceutical products based on pharmacokinetic studies (e.g. bioavailability/bioequivalence) in humans and animals, including validation of *in vitro* results with *in vivo* studies. (2) *In vitro* drug release characterization of pharmaceutical products, particularly oral and dermal, using dissolution and/or diffusion (absorption/penetration through the skin) techniques. (3) Analytical methods development/validation for drug disposition evaluation in humans and animals (4) Data analysis using sophisticated (SAS) and general-purpose (e.g., M.S. Excel) software.

Record of Productivity & Recognitions: Recipient of (1) Lifetime Achievement award (2015, Indus Foundation, India); (2) 2007 Deputy Minister's (Canada) Award of Excellence in Science; (3) Excellence in Science Award (2007, Health Canada).
Publications (56), including three book chapters and two U.S. patents. Presentations at scientific meetings/interviews =96 (including 46 invited). Unpublished Departmental or external reports=23. A book co-author 'Slaying the Vaccine Devil: Death of Germ Theory' in progress (anticipated publication date early 2022).
Collaborative and Lead Roles:

1. Principal organizer and co-chair of DIA-sponsored workshops on drug dissolution testing (London, England, June 2001 and Toronto, October 1999). Twenty plus invited speakers mostly from Europe and North America, presented their research findings.

2. Principal organizer of four international collaborative studies conducted under the auspices of Laboratories and Medicines Control section of International Pharmaceutical Federation (FIP), The Hauge, Netherlands (usually 20 - 30 countries participate). The objective of the studies is to assess and compare the quality of pharmaceutical products available in different countries for developing internationally harmonized standards.

3. Invited professor at the Centre of Excellence, Punjab University, Lahore, Pakistan.

4. Invited lecturer (1998-2009), the Department of Pharmacy, the University of Montreal, to give a 3-hr evening seminar on "In vitro/in vivo Correlation."

5. Co-director of research of an M.Sc. student from the University of Montreal. [(Funding received=$150,000]

6. Collaborative research project with University of Saskatchewan [Supervision of a Post-Doc fellow, Funding received=$50,000]

1981 - 1984 Research Foods Ltd., Toronto

Group leader: "Biological toxin production group," a technology transfer project from Agriculture Canada to produce gram quantities of vomitoxin using microbial culture system (50-100 L/batch).

Research chemist: Development and validation of analytical methods to determine trace components of various food and agricultural commodities using chromatographic and spectroscopic techniques.

1974 - 1976 Lecturer, Chemistry Department, University of Engineering and Technology, Lahore, Pakistan. Taught chemistry courses to undergraduate classes of chemical, metallurgical, and petroleum engineering.

EDUCATION:

Ph.D. (1980) In Organic Chemistry from State University of Ghent, Ghent, Belgium.
Thesis: A Chromatographic Investigation of Pepper Alkaloids.

M.Sc. (1974) With Organic Chemistry major from University of Punjab, Lahore, Pakistan
Thesis: A Critical Study of Benzoylacetone Complexes.

CONTINUING EDUCATION:

(1996) Graduate course in "Probability and Statistics," U. of Ottawa (Canada).
(1991) Graduate course "Human Physiology," U. of Ottawa (Canada).
(1990) Advanced Pharmacokinetics course, U. of California, San Francisco (USA).
(1989) Pharmacokinetics course, University of Wisconsin, Madison (USA)

APPENDIX

PATENTS:

1. United States patent (#US 6,676,285, Jan. 2004). Low-speed precision stirring/mixing device.

2. United States patent (#US 7,008,101, Mar. 2006). Method and apparatus for reproducible dissolution testing of pharmaceutical products.

SUBJECT-MATTER EXPERT: In the High Court of South Africa, Case No: 5852/2021 (2021). Virus (SARS-2-CoV-2) isolation.

BOOK: Dr. Saeed Qureshi, Dr. Judy Wilyman, Robert Beatty, John O'Sullivan. "**Slaying the Virus and Vaccine Devil**." Anticipated publication date, early 2023.

INTERVIEWS:

1. Dr. Saeed Qureshi - Non-sense non-science – with Daniel Roytas of Humanley (link)

2. Logical Conclusion – Invalid test, No Valid Results (Interviewed by Truth Summit), (*link*)

3. COVID-19: An online discussion with Dr. Andrew Kaufman (USA) and Kamala Taris (Czech Republic) (Link)

BOOK CHAPTERS:

1. Saeed A. Qureshi. **Quality of pharmaceutical products for human use – underlying concepts and required practices**, published in Drug Delivery Trends: Expectations And Realities Of Multifunctional Drug Delivery Systems Volume 3 Edited by Ranjita Shegokar, PhD., Elsevier, March 2020

2. Saeed A. Qureshi. **Tablet Testing**. Encyclopedia of Pharmaceutical Technology, James Swarbrick (ed.), Marcel Dekker, Inc., New York, 2012

3. Saeed A. Qureshi. **Pharmacokinetics: Basic concepts for dosage regimen considerations**. Chapter in *Sleep Disorders: Pharmacology and Therapeutics*. Pandi-Perumal, Verster, Monti, Lader & Langer (eds), Informa Healthcare, London, UK. *2008*

PUBLICATIONS:

1. Saeed A. Qureshi. **Numerous articles on the subject of virus testing, isolation, and vaccine developments** (https://principia-scientific.com/). 2020 – to date.

2. Saeed A. Qureshi. **Numerous articles on the subject of assessing the quality of pharmaceutical products**. (www.bioanalyticx.com, www.drug-dissolution-testing.com). 2000 – to date

3. Qureshi, SA. **A Critical Assessment of Current Practices of Drug Dissolution Testing – Irrelevancies, their Causes, and Suggestions to Address These**. J App Pharm 2015, 7:4

4. Qureshi SA. **Limitations of Some Commonly Described Practices in Drug Dissolution Testing and Suggestions to Address These**. *Am. Pharmaceutical Reviews. 2011*: (Jan/Feb), 44-49.

5. Qureshi, SA. **Determining blood concentration-time (C-t) profiles from in vitro dissolution results and product evaluation – carbamazepine**. (Link)

6. Qureshi, SA. **Reporting and Analyzing Drug Dissolution Results – A Systematic Approach**. *Am. Pharmaceutical Reviews*. 2010: (May/June), 11-15.

7. Qureshi, SA. ***In Vitro-In Vivo* Correlation (IVIVC) and Determining Drug Concentrations in Blood from Dissolution Testing – A Simple and Practical Approach.** *The Open Drug Delivery Journal,* 2010, *4,* 38-47 (Link).

8. Qureshi SA. **A Crescent-shaped Spindle for Improved Dissolution Testing**. *Pharmeuropa Bio & Scientific Notes*, 1:2009: 55-66.

9. Qureshi SA. **Drug Dissolution Testing: Selecting a Dissolution Medium**. *Am. Pharmaceutical Reviews*. 1:2009:2-5.

10. Qureshi SA. **A simple and economical approach/concept to evaluate quality of pharmaceutical products based on an improved dissolution testing methodology**. *The Open Drug Delivery Journal*. 2;2008:33-37 (Link)

11. Qureshi SA. **Performance verification of drug dissolution apparatuses – controversy, its causes and a suggested solution.** *Am. Pharmaceutical Reviews*. 11;2008:11-15.

12. Qureshi SA. **Development and validation of drug dissolution methods – a rational and systematic approach**. *Am. Pharmaceutical Reviews*.10(3);2007:41-45.

13. Qureshi SA. **Comparative impact of stirring and shearing in drug dissolution testing with USP Paddle and Crescent-shaped spindles.** *Dissolution Technologies.* 13(1);2006:25-30.

14. Qureshi SA. **Developing discriminatory drug dissolution tests and profiles: some thoughts for consideration on the concept and its interpretation.** *Dissolution Technologies.* 13(4); 2006:18-23.

15. Qureshi SA. **The challenges of dissolution testing today: two perspectives.** *Tablets and Capsules*, 4(5);2006:28-36.

16. Qureshi SA. **Response to a letter to the Editor on an article "A New Crescent-shaped Spindle For Drug Dissolution Testing - But Why a New Spindle?** *Dissolution Technologies.* 12; 2005:26-32.

17. Qureshi SA. **Biopharmaceutical principles for drug products development and assessment: Bioavailability, bioequivalence and dissolution evaluation of solid oral products"** *Pharmaceutical Canada*. June 2005:29-34.

18. Qureshi SA. **Drug dissolution testing- deficiencies and some suggestions for improvement**. *Am. Pharmaceutical Reviews*. 8;2005:52-55.

19. Qureshi SA. **Improved drug dissolution and product characterization using the crescent-shaped spindle.** *J. Pharm. Pharmacol.* 56; 2004:1135-1141.

20. Qureshi SA. **Choice of rotation speed (rpm) for bio-relevant drug dissolution testing using a Crescent-shape spindle.** *Eur. J. Pharm. Sci.* 23;2004:271-275.

21. Qureshi SA. **A new crescent-shaped spindle for drug dissolution testing - but why a new spindle?** *Dissolution Technologies.* 11(4);2004:13-18.

22. Qureshi SA and Shabnam J. **Applications of a new device (spindle) for improved characterization of drug release (dissolution) of pharmaceutical products.** *Eur. J. Pharm. Sci.*, 19;2003:291-297.

23. Qureshi SA and Shabnam J. **Cause of high variability in drug dissolution and its impact on setting tolerances**. *Eur. J. Pharm. Sci.* 12;2001:271-276.

24. Qureshi SA. **Drug dissolution testing - the technique, its role and limitations"** *Pharmaceutical Canada*. Spring 2001, 25-29.

25. Qureshi SA and McGilveray IJ. **"Typical" variability in drug dissolution testing: study with USP and FDA calibrator tablets and a marketed drug (glibenclamide) product**. *Eur. J. Pharm. Sci*.7;1999: 249-258.

26. Jiang M and Qureshi SA. **Assessment of *in vitro* percutaneous absorption of glycolic acid through human skin sections using a flow-through diffusion cell system**. *J Derm Sci*. 18;1998: 181-188.

27. Jiang M and Qureshi SA. **In vitro evaluation of percutaneous absorption of an acyclovir product using intact and tape-stripped human skin**. *J. of Pharmacy and Pharmaceutical Sciences*. 1; 1998:102 -107.

28. Qureshi SA and McGilveray IJ. **Assessment of pharmaceutical quality of furosemide tablets from multinational markets**. *Drug Devel. Ind. Pharm*. 24(11);1998: 995-1005.

29. Boivert J, Caillé G, McGilveray IJ and Qureshi SA. **Quantification of ketoprofen enantiomers in human plasma based on solid-phase extraction and enantioselective column chromatography**, *J. Chromatogr. B*. 690;1997: 189-193.

30. Qureshi SA. **Calibration - The USP dissolution apparatus suitability test.** *Drug Inf J*. 30;1996: 1055-1061.

31. McGilveray IJ and Qureshi SA. **Role of *in vitro* dissolution test -overview and recent progress of risk-assessment procedure**. Bio International '96 Proceedings, Eds. K. Midha and T. Nagai, FIP Bio International '96 Proceedings, Business Center for Academic Societies Japan (BCASJ), pp. 253-258 (1996).

32. **FIP Guidelines for Dissolution Testing of Solid Oral Products**, Published in *Pharmacopeial Forum*, **21** (1995) 1371-1382, and Pharm. Ind. **57** (1995) 362-369. The guidelines are developed by the contributions from 18 scientists, representing different countries, including two from Canada (Qureshi, S.A, & McGilveray, I.J.).

33. Qureshi SA and McGilveray IJ. **A critical assessment of the USP dissolution apparatus suitability test criteria**. *Drug Develop Ind Pharm.* 21(8);1995: 905-924.

34. Blume H, Qureshi SA, Ali SL and McGilveray IJ. **Evaluation of pharmaceutical quality of prednisone tablets from multinational markets**. *Drug Develop and Ind Pharm*. 21(8);1995: 925-942.

35. Qureshi SA, Caillé G, Lacasse Y (*the late*) and McGilveray IJ. **Pharmacokinetics of Two Enteric-Coated Ketoprofen Products in Humans with Or Without Co-Administration of Omeprazole**". *Pharm. Res*. 11;1994:1669-72.

36. Qureshi SA and McGilveray IJ. **Impact of different de-aeration methods on the USP dissolution apparatus suitability test criteria**. *Pharmacopeial Forum*. 20;1994: 8565-8566.

37. Qureshi SA, Caillé G, Brien R, Piccirilli, G, Yu V and McGilveray IJ. **Application of a flow-through dissolution method for the evaluation of oral formulations of nifedipine**. *Drug Develop Ind Pharm*. 20(11);1994:1869-1882.

38. Qureshi SA, Laganière S, Caillé G, Gossard D, Lacasse Y, and McGilveray, IJ. **Effect of an acute dose of alcohol on the pharmacokinetics of oral nifedipine in humans** *Pharm. Res*. 6;1992:683-686.

39. Qureshi SA, Buttar H.S. and McGilveray IJ. **Lithium-induced nephrotoxicity in rats following subcutaneous multiple injections and infusion using mini-osmotic pumps**". *Fundam. Appl. Toxicol*. 18;1992:616-620.

40. Qureshi SA and McGilveray IJ. **Dissolution studies of Selegiline tablets** Pharmacopeial *Forum* 17;1991:1973-1976.

41. Gallicano KD, McGilveray IJ, Qureshi SA, Nitchuk W, Chakraborty B, Boyd C. **Situation paper: comparative Bioavailability of oral contraceptive products**". *Clin. Biochem*. 24;1991:107-111.

42. Qureshi SA, Laganieré S, McGilveray IJ, Lacasse Y and Caillé G. **Nifedipine-alcohol interaction**. *JAMA* 264;1990:1660-1661.

43. Qureshi SA and Huang H. **Determination of B_6 vitamers in serum by simple isocratic high performance liquid chromatography**. *J Liquid Chromatography*. 13;1990:191-201.

44. Qureshi SA and Buttar H.S. **A comparative study of the pharmacokinetics of propranolol and its major metabolites in the rat after oral and vaginal administration**. *Xenobiotica*. 19:1990:883-890.

45. Foster BC, Buttar HS, Qureshi SA and McGilveray IJ. **Propranolol metabolism by Cunninghamella bainieri**". *Xenobiotica*. 19;1989:539-546.

46. Qureshi SA and Buttar H.S. **High performance liquid chromatographic determination of propranolol and its metabolites in rat serum**. *J. Chromatogr*. 431;1988:465-470.

47. Terhune SJ, Nguyen NV, Baxter JA, Pryde D.H. and Qureshi SA. **Improved gas chromatographic method for quantitation of deoxynivalenol in wheat, corn and feed**. *J Assoc Off Anal Chem*. 67;1984:1102-1104.

48. Baxter JA, Terhune SJ and Qureshi SA. **Use of chromotropic acid for improved TLC visualization of tricothecine mycotoxins**. *J. Chromatogr*. 261;1983:130-133.

49. Verzele M, Redant G, Qureshi SA, and Sandra P. **High temperature quantitative glass capillary gas chromatography - analysis of piperine and quinine-quinidine**. *J. of Chromatogr*. 199;1980:105-112.

50. Verzele M and Qureshi S. **HPLC determination of piperine in pepper and pepper-Extracts**. *Chromatographia*. 13;1980:241-243.

51. Verzele M, Mussche P and Qureshi SA. **High performance liquid chromatographic analysis of pungent principles of pepper and pepper-extracts**. *J. Chromatogr*. 172:1979:493-497.

SEMINARS (Invited)

1. Qureshi SA. **Drug Dissolution Testing – Basic Principles & Practices**, Rowan University (New Jersey, United States). October 2015.

2. Qureshi SA. **Drug Dissolution Testing For Global Bioequivalence Requirements**. 2nd Annual Bioequivalence Conference: Intersection between Science and Regulatory Summit, Philadelphia, PA, USA. September 29-30, 2015

3. Qureshi SA. **Drug Dissolution Testing - *In vitro/in vivo* Correlations**, Department of Pharmacy, University of Montreal, Montreal, April, 2011.

4. Qureshi SA. **Defining and establishing quality of drug products (tablet/capsule) – focus on product development and manufacturing** (Indo-Global Pharma Expo & Summit, Hyderabad, India 2015).

5. Qureshi SA. **Why is assessing the quality of products (tablets/capsules) so confusing and difficult? Some underlying scientific reasons and explanations** (Indo-Global Pharma Expo & Summit, Hyderabad, India 2015).

6. Qureshi SA. **Drug Dissolution Testing: Recent Advances and Developments**. Presentation (video-conference) to KRKA-Pharmaceuticals, Slovenia. February 6, 2007

7. Qureshi SA. **Developing An Improved Dissolution Method**. IPA Workshop on Dissolution Testing,Toronto. April 3-4,2006.

8. Qureshi SA. **Drug Dissolution Testing - *In vitro/in vivo* Correlations**, Department of Pharmacy, University of Montreal, Montreal, April, 2006.

9. Qureshi SA. **Developing A Robust Dissolution Method – Some Considerations.** PharmEX Pro 2005, Montreal, November 1-2, 2005

10. Qureshi SA. **Problems and solutions in dissolution testing**, Canadian Society of Pharmaceutical Sciences Workshop on Dissolution Testing. June 2-3, 2005.

11. Qureshi SA. **Dissolution Testing Course**. Lab-based hands-on Training on Dissolution Testing AAPS, Toronto, February 8-9, 2005.

12. Qureshi SA. **Flow-through (USP 4) Apparatus – Experience and Views**. *Seminar and Workshop on Novel Developments In Apparatus 4 and Fiber Optic Dissolution*. Horsham, PA June 2004

13. Qureshi SA. **Developing Drug Dissolution Methods and Setting Tolerances**, *PSG/TPD Quality Workshop*. May 2004.

14. Qureshi SA. **Drug Dissolution Testing - *In vitro/in vivo* Correlations**, Department of Pharmacy, University of Montreal, Montreal, April, 2004.

15. Qureshi SA. **Deficiencies of the USP Paddle Apparatus and a Possible Solution**. *AAPS Workshop on "Dissolution: New Technologies and Regulatory Initiatives"*, Bethesda, MD., March 2004.

16. Qureshi SA. ***In Vitro* Drug Dissolution Testing**, *CAPPP Workshop*, Toronto, September 2003.

17. Qureshi SA. **Pharmacokinetics - Bioavailability/Bioequivalence Studies - Important Steps in Drug Development.** *H. E. J.-COMSTECH (CPC) International Workshop on The Development of Medicines from Plants.* Karachi, Pakistan. September 2003.

18. Qureshi SA. **Drug Dissolution Testing - *In vitro/in vivo* Correlations**, Department of Pharmacy, University of Montreal, Montreal, April, 2003.

19. Qureshi SA. **Pitfalls of current approaches for dissolution testing of pharmaceutical products**. *IPA-Workshop on Current Status and Future Challenges in Drug Dissolution Testing*. Toronto, May 2003.

20. Qureshi SA. ***In vitro* Drug Dissolution Testing**, DIA-Pakistan Workshop, Karachi, December 2002.

21. Qureshi SA **Reproducibility and Relevancy of Drug Dissolution Results**. 2002 VG-International Convention on Quality for Pharmaceutical Industry, Toronto, September 2002.

22. Qureshi SA. **Drug Dissolution Testing - Obtaining Reproducible and Relevant Results**, 2002 Meeting of Laboratories and Medicines Control Services Section of FIP, Kiev, Ukraine, May 2002.

23. Qureshi SA. **Drug dissolution testing - *In vitro/in vivo* correlations**, Department of Pharmacy, University of Montreal, Montreal, April, 2002.

24. Qureshi SA. **Instrument (Paddle and Basket Apparatuses) limitations for developing tolerances**. Drug Dissolution Group 3rd Annual Meeting, Research Triangle Park, NC., May 3-4, 2000.

25. Qureshi SA. **Suspensions: A extension of solid oral dosage forms**. The Royal Pharmaceutical Society's Pharmaceutical Sciences Group and the FIP Working Group on Dissolution Testing Workshop on "Dissolution Testing of Special Dosage Forms", London, UK, Sept. 2-3, 1999.

26. Qureshi SA. **Drug dissolution testing - *In vitro/in vivo* correlations**. Department of Pharmacy, University of Montreal, Montreal, March 10, 1999.

27. Qureshi SA. **Drug Product dissolution testing - current status and future challenges**. Continuing Education Workshop/Seminar, at Therapeutic Products Directorate, November 25, 1998.

28. Qureshi SA. **Drug Dissolution testing: apparatus suitability test and setting tolerances for products**. Pharmaceutical Sciences Group Seminar, Toronto & Montreal, June 2 & 9, 1998.

29. Qureshi SA. **Variability in dissolution testing and its impact on calibration of USP apparatuses 1 & 2 and testing of a commercial drug product**. The World Congress of Pharmacy and Pharmaceutical Sciences '97, Vancouver, BC, 1997.

30. Qureshi SA. **Variability using USP2 with NCDA prednisone, USP calibrator and glyburide tablets**. The 1997 AAPS Annual Meeting & Exposition, November, 1997, Boston, MA

31. Qureshi SA. **Drug dissolution testing - technique and its importance to patients**, Department of Pharmacology, University of Montreal, Montreal, Quebec, February, 1997

32. Qureshi SA. **The role of comparative *in vitro* dissolution studies; problems and solutions**.WHO sponsored Henry Stewart Studies Conference on " Understanding Bioequivalence and Therapeutic Equivalence and their Documentation for New Generic Applications" London, UK, September, 1996

33. McGilveray IJ and Qureshi SA. **Role of in-vitro dissolution test: Overview and recent progress of a risk assessment procedure**. Bio International 1996, Tokyo, Japan.

34. Qureshi SA. **Calibration of dissolution equipment - Limitations.** 1996 Meeting of Official Laboratories and Medicines Control Services Section of FIP, Copenhagen, Denmark, May 1996.

35. Qureshi SA, Graham ML, Sattar SA and McGilveray IJ. **An *ex vivo* human skin model to evaluate absorptive, toxicological and germicidal activities of topicals**. Ottawa Life Science Congress, Oct., 1995, Ottawa, Ontario.

36. Qureshi SA. **Calibration - The USP dissolution apparatus suitability test**. DIA Sponsored Dissolution Workshop, Toronto, Canada, June 1995.

37. Qureshi SA. **Some examples of *in vitro - in vivo* drug release characterization and their relevance to drug product evaluation**. University of Montreal, Montreal, November '94.

38. Qureshi SA. **Survey of variability in the dissolution apparatus suitability test criteria**. Pharmaceutical Sciences Group Seminar, Toronto & Montreal, September '94.

39. McGilveray IJ and Qureshi SA. **How to set specifications for *in vitro* quality control of dosage forms**? Pharmacy Word Congress, Lisbon, Portugal, September '94.

40. McGilveray IJ and Qureshi SA. ***In Vivo/In Vitro* correlation: How to assess dissolution specifications for quality control**". Introductory Remarks at the Pre-Conference Satellite Symposium, Bio-International '94, Munich, June '94.

41. Qureshi SA. **Value of tape stripping: A prominent technique, but is it useful?"** 3rd International Conference on Prediction of Percutaneous Penetration, La Grande Motte, France, April '93.

42. Qureshi SA. **Dissolution apparatus calibration & comparative dissolution studies**. Pharmaceutical Sciences Group Seminar, Toronto & Montreal, April '93.

43. McGilveray IJ and Qureshi SA. **Some dissolution questions - answered (?).** "Experts" Meeting for Developing Dissolution Guidelines, FDA, Rockville, November '93.

44. Bailey K, Qureshi SA and McGilveray IJ. **In vitro and *In vivo* drug release characterization**. Invited paper included in the workbook for the "International Open Conference on Dissolution, Bioavailability, Bioequivalence, Toronto, Canada, June 15-18, 1992.

PAPERS PRESENTED AT SCIENTIFIC MEETINGS

1. Saeed Qureshi, Jacques Gagnon, Jean-Francois Paradis, Mohammed Gherras, and Amina Melgar. **Application of a dissolution test using crescent-shaped spindle (css) to evaluate assay and uniformity of dosage unit parameters.** Annual Meeting of the AAPS, Washington, DC. October 2011.

2. Qureshi SA. **Improved in vitro model to assess drugs release characteristics of products for their absorption from human gastrointestinal tract.** *1st International Conference on Drug Design and Discovery (ICDDD)*. Dubai, UAE. February 4-7, 2008.

3. Qureshi SA. **Choice of a single reference (calibrator?) tablet product for drug dissolution testing using crescent-shaped spindles**. Annual Meeting of the AAPS, Nashville, TN. November 2005

4. Qureshi SA. **Improved drug dissolution and product characterization using crescent-shaped spindle**. Annual Meeting of the AAPS, Baltimore, MD. November 2003.

5. Qureshi SA. **Drug release characteristics of carbamazepine products using different spindles**. Health Canada Science Forum, November, 2003, Ottawa

6. Qureshi SA. **Impact of varied hydrodynamics, using different spindle types and rpms, on drug (carbamazepine) dissolution testing**. Annual Meeting of the AAPS, Salt Lake City, Utah. October 2003.

7. Qureshi SA. **Drug release characteristics of carbamazepine products using different spindles**. Health Canada Science Forum, November, 2003, Ottawa

8. Qureshi SA and Shabnam J. **An improved stirring/mixing device for drug dissolution testing.** Annual Meeting of the AAPS, Toronto, November 2002.

9. Qureshi SA and Shabnam J. **Application of a new stirring/mixing device for improved drug release (dissolution) characterization to assess the quality of pharmaceutical products**. Health Canada Science Forum, November, 2002, Ottawa.

10. Moody RP, Qureshi SA and Akram M. **Calibration of *in vitro* dermal absorption test systems: Inter-system variation in tritiated-water Kp values.** 41st Annual Meeting of Society of Toxicology, Nashville, TN, March 2002.

11. Qureshi SA. **Assessment of pharmaceutical quality, in particular drug release characterization, of amoxicillin oral suspension products.** The Spring Meeting of the LCM Section of FIP, Brussels, Belgium, May 2000.

12. Qureshi SA., Instrument **(Paddle and Basket Apparatuses) limitations for developing tolerances.** DIA Workshop on Drug Dissolution Testing: Current Status and Future Challenges, Toronto, October 4-5, 1999.

13. Jiang M and Qureshi SA. **Assessment of percutaneous absorption of glycolic acid (G.A.) through human skin sections using a flow-through diffusion cell system.** Annual Meeting of the AAPS, San Francisco, CA, November 1998

14. Qureshi SA. **Dissolution characteristics of USP calibrators *vs* a commercial drug product**. The Spring Meeting of the OLCMS Section of FIP, Bern, Switzerland, May 1997.

15. Qureshi SA and McGilveray IJ. **"Typical" variability in drug dissolution testing: study with USP and FDA calibrator tablets and a marketed drug (glyburide) product.** The 1996 Annual Meeting of the AAPS, Boston, MA, November 1997.

16. Qureshi SA, Graham ML, Sattar SA, Bujaki S and McGilveray IJ. **As assessment of viability of human skin sections obtained from different anatomical sites using a flow-through diffusion cell system.** 1996 Annual Meeting of the AAPS, Seatle, WA., October 1996.

17. Boivert J, Qureshi SA, Caillé G and McGilveray IJ. **Pharmacokinetics of sustained-release ketoprofen products with or without omeprazole in healthy human volunteers**. 1996 Annual Meeting of the AAPS, Seatle, WA., October 1996.

18. Qureshi SA and McGilveray IJ. **Pharmaceutical quality of furosemide drug products available in different countries - an FIP collaborative study.** 10th Annual Meeting of the AAPS, November '95.

19. Qureshi SA. **Dissolution testing - some recent observations and developments**. AAPS-USP Workshop on Dissolution Testing, Washington, Sept., 1995

20. Boisvert J, Caillé G, McGilveray IJ and Qureshi SA. **Identification et quantification des énantiomères du kétoprofène dans le plasma humain par extraction en phase solide et chromatographie liquide stéréospécifique**. Club de Recherches Cliniques du Québec, September 1995, Bromont, Québec.

21. Boisvert J, Caillé G, McGilveray IJ and Qureshi SA. **Quantitation of ketoprofen in human plasma based on solid phase extraction and enantioselective column chromatography.** 10th Annual Meeting of the AAPS, November '95.

22. Boisvert J, Caillé G, McGilveray IJ and Qureshi SA. **Determination of ketoprofen enantiomers based on enantioselective column chromatography and its application to modified release drug dissolution testing.** Ottawa Life Science Congress, Oct., 1995, Ottawa, Ontario.

23. Qureshi SA & McGilveray IJ. **Multinational survey of quality of furosemide tablets - an update.** Presentation at the FIP/OLMCS Section Meeting, August 1995, Stockholm, Sweden.

24. Qureshi SA and McGilveray IJ. **Study proposal and protocol for multinational collaborative research project to assess the variability of the usp dissolution apparatuses.** FIP/OLMCS Section Meeting, August 1995, Stockholm, Sweden.

25. Qureshi SA. **Dissolution studies of furosemide products from the multinational markets.** Spring Meeting of the OLMCS Section of the FIP, The Hague, Netherlands, April '95.

26. Grundy JS, Foster RT, duSouich P, Qureshi SA, Saunier C and Caillé G. **A single-dose pharmacokinetics of three prolonged-action (PA) nifedipine formulations**. 9th Annual Meeting of the AAPS, San Diego, California, November '94.

27. Qureshi SA, Caillé G, Brien R and McGilveray IJ. **Drug release characterization of extended-release nifedipine products using a flow-through dissolution apparatus**. 21st Int'l Symposium on Controlled Release of Bioactive Materials, Nice, France, June '94.

28. Qureshi SA, Brien R and McGilveray IJ. **Dissolution Studies of Phenytoin Products From the Canadian Market.** Spring Meeting of the OLCM Section of the FIP, Stockholm, June '94.

29. Qureshi SA and McGilveray IJ. **Survey of variability in the USP dissolution calibrators results**. 9th Annual Meeting of the AAPS, San Diego, California, November '94.

30. Qureshi SA, Caillé G, Brien R, Piccirilli G, Yu V and McGilveray IJ. **Application of a flow-through dissolution method for the evaluation of oral formulations of nifedipine**. 8th Annual Meeting of the AAPS, Orlando, FL, November '93.

31. Qureshi SA, Caillé G, Lacasse Y (*the late*), and McGilveray IJ. **Pharmacokinetics of two enteric-coated ketoprofen products in humans with or without co-administration of omeprazole**. 5th European Congress of Biopharmaceutics and Pharmacokinetics, Brussels, Belgium. April '93.

32. Qureshi SA, Bronaugh R, Somers D, Franklin C and McGilveray IJ. ***In vitro* characterization of skin absorption of hydrocortisone from topical formulations using flow-through diffusion cells**. 3rd International Conference on Prediction of Percutaneous Penetration, La Grande Motte, France, APRIL '93.

33. Qureshi SA, Brien R and McGilveray IJ. **Dissolution study of carbamazepine products from the canadian market.** Spring Meeting of the OLMCS Section of the FIP, Edinburgh, April '93.

34. Qureshi SA, Caillé G, Lacasse Y (*the late*) and McGilveray IJ. ***In vitro* and *in vivo* (in healthy human volunteers) evaluation of enteric-coated ketoprofen products at potentially elevated stomach pH values.** World Pharmacy Congress, Tokyo, September '93.

35. Qureshi SA, Ormsby ED and McGilveray, IJ. **Regression analysis for analytical method validation using a standard statistical software**. Pittsburgh Conference (PITTCON '92), New Orleans, Louisiana, March 9-13, 1992.

36. Dawson BA, Qureshi SA and Black DB. **Application of ^{1}H-NMR spectroscopy for enantioselective evaluation of the dissolution of ketoprofen formulations**. 33rd ENC Conference, Pacific Grove, CA., Mar 29- Apr. 2, 1992.

37. Qureshi SA, Pawell C and McGilveray IJ. **Dissolution studies of prednisone tablets**. FIP Section of Official Laboratories and Medicines Control Services Meeting, Eschborn, Germany, May 18-19, 1992.

38. Carignan G, Gallicano K, Qureshi SA and McGilveray IJ. **Dissolution and disintegration studies of selected lots of conjugated estrogen tablets**. Presentation to USP Open Meeting, Washington, September 29, 1992.

39. Gallicano K, Ormsby ED, Qureshi SA, Beaulieu N, Laganière S and McGilveray IJ. **Some suggestions for presentations of analytical validation for pharmacokinetics data in new drug submissions**. 52nd FIP International Congress, Lyon, France, (September, 14-18, 1992).

40. Qureshi SA, Gallicano KD, Ormsby ED and McGilveray IJ. **Presentation and evaluation of analytical data from comparative drug-bioavailability studies.** Poster presentation at the 7th Annual Meeting of AAPS, San Antonio, TX, Nov '92.

41. Qureshi SA, Buttar H.S. and McGilveray IJ. **Pharmacokinetics (P.K.) and disposition of lithium in the rat after single and multiple subcutaneous (S.C.) dosing**. 1991 Annual SOT Meeting, Dallas, TX. February 25 - March 1, 1991.

42. Qureshi SA and McGilveray IJ. **Dissolution studies of selegiline tablets**. Pharmacy World Congress '91, Washington, D.C. September, 3, 1991

43. Qureshi SA, Buttar HS., Thomas BT and McGilveray IJ. **Comparison of nephrotoxicity in rats following intermittent or continuous subcutaneous infusion of lithium**. Pharmacy World Congress '91, Washington, D.C. September, 3, 1991.

44. Qureshi SA, Laganieré S, McGilveray IJ, Lacasse Y and Caillè G. **effect of an acute dose of alcohol on the pharmacokinetics (P.K.) of oral nifedipine**. 5th Annual meeting of AAPS, November 4-9, 1990, Las Vagas, Nevada.

45. Qureshi SA, Buttar HS, Thomas BH and McGilveray IJ. **Lithium-induced nephrotoxicity in rats following subcutaneous multiple injections (smi) or infusion using mini-osmotic pumps (MOP)**. 33rd Annual meeting

of Canadian Federation of Biological Societies" June 14-16, 1990 Halifax, N.S.

46. Buttar H.S. and Qureshi SA. **Disposition of lithium in pregnant and nonpregnant rats**. 29th Annual Meeting of Society of Toxicology, Miami Beach, FL, Feb. 12-16, 1990.

47. O'Leary G, Qureshi SA, Laganiere S, McGilveray IJ, Boylan JF, Hassard P and Teasdale SJ. **Intranasal Nifedipine for post-bypass hypertension - hemodynamics and pharmacokinetics**. Annual meeting of Canadian Anaesthetist, Vancouver, BC, June 1990.

48. Qureshi SA and Huang H. **Separation and determination of vitamin B_6 in serum by high performance liquid chromatography**. International Symposium on Drug Safety, September 28-29, 1989, Ottawa, Canada.

49. Qureshi SA and Buttar H.S. **Pharmacokinetic studies of propranolol following oral and vaginal administration in rat**. Reproductive Biology Workshop, University of Ottawa, Ottawa, Canada., May 25, 1989.

50. Foster BC, Buttar HS, Qureshi SA and McGilveray IJ. **Propranolol metabolism by *Cunninghamella echinulata***. 1987 ISSX/SOT Clearwater Symposium, Clearwater, FL, November 8-13, 1987.

UN-PUBLISHED DEPARTMENTAL OR EXTERNAL REPORTS:

1996

1. Qureshi SA. **Dissolution testing of lipid-based dosage forms - soft-gelatin capsules and suppositories**. A literature review report submitted to the client Bureau.

2. Qureshi SA. **A drug dissolution study of 5-ASA products and its relevance to *in vivo* (in humans) drug release characteristics.** A report to client Bureau.

3. Qureshi SA. **A drug dissolution study of extended-release verapamil products.** A laboratory research assignment report to Client Bureau.

1995

4. Qureshi SA. NDS review report, "**A two-way, single-dose, fasting bioavailability study of sustained-release propranolol 160 mg capsules in normal healthy non-smoking male volunteers**".

1994

5. Qureshi SA. **Ketoprofen-omeprazole (multiple-dose) interaction study.** Proposal for a collaborative research project to the University of Montreal.

6. Qureshi SA. NDS review report - **A comparative three-way cross-over bioavailability study of 25 mg and 50 mg indomethacin capsules verses indocid 50 mg**.

7. Qureshi SA and McGilveray IJ. **Study protocol - multinational survey of quality of furosemide tablets**. The study to be conducted under the auspices of OLCMS Section of FIP.

8. Qureshi SA. **Drug release characteristics (dissolution) analysis of phenobarbital tablets**. A research assignment from the HPB-Vancouver Field Operation Laboratory.

9. Qureshi SA and McGilveray IJ. **Inter-laboratory variability in drug release from a carbamazepine product *vs* USP calibrator.** Results submitted to Dr. Davidson of U.K., the organizer of the 1994 Multinational Study Analysis.

1993

10. Qureshi SA. **Guidelines for the conduct and analysis of drug dissolution studies.** Draft submitted to the Bureau of Non-prescription Drugs. October '93.

11. Qureshi SA and McGilveray IJ. **HPB sponsored survey of the Canadian pharmaceutical industry to assess the variability of USP dissolution calibrators.** Results presented at a FDA meeting, November '93.

12. Qureshi SA and McGilveray IJ. **Evaluation of prednisone dissolution data by mathematical modelling (linearization)**. Analysis of data obtained from the WHO/FIP sponsored multinational collaboration study. Report submitted to the study coordinator.

13. Qureshi SA. **Dermal absorption (penetration) of drugs**. A research project proposal submitted to the client Bureaus.

14. Qureshi SA. **S/NDS - Acyclovir cream 5%**. Assessment report on the *in vitro* skin absorption data and methodology. Review report prepared for BHPD, June '93.

1992

15. Qureshi SA and McGilveray IJ. **Dissolution Guidelines** incorporated in "Acceptable methods-Drug Directorate Guidelines.

16. Black DB, Dawson BA and Qureshi SA. **Utilizing nuclear magnetic resonance (NMR) spectroscopy for assessing drug isomeric composition: ketoprofen enantiomeric composition.** A BDR Report.

17. Qureshi SA, Pawell C and McGilveray IJ. **Dissolution studies of prednisone tablets**. A BDR Report submitted to the BPS.

18. Qureshi SA. **Azathioprine bioavailability study proposal.** Evaluation of a study proposal from the Industry. Report submitted to the Bureau of Pharmaceutical Surveillance and to the Branch's EAC committee on Bioavailability.

1991

19. Qureshi SA. **A two-way single dose food-effect bioavailability study of sustained-released diclofenac sodium 100 mg tablets in normal healthy male volunteers**. New drug submission (application), report prepared for the Bureau of Pharmaceutical Sciences.

20. Qureshi SA, Brien R and McGilveray IJ. **A comparative dissolution study of glibenclamide tablets from the Canadian market - A collaborative study sponsored by the World Health Organization (WHO) and Zentrallaboratorium Deutscher Apotheker (ZLDA) of Germany** reports submitted to WHO & ZLDA.

1990

21. Qureshi SA, McGilveray IJ and Bayne A. **Doxepin dissolution study report**. A BDR report was prepared and submitted to the respective Bureaux to establish quality control criteria for drug quality evaluation, Dec. '90.

22. Qureshi SA and Ormsby E. **Use of regression method for calibration curves in analytical method validation** . A report presented to EAC on Bioavailability which describes some concerns regarding the use of regression method for Bioavailability and bioequivalence determination in drug submissions (NDS).

1989

23. Qureshi SA, McGilveray IJ, Foster BC, Wilson DL and Bayne A. **Diltiazem dissolution study report**. A dissolution study report describing results of experiments conducted as per protocol.